Repetitive and restricted behaviour (Sensory Motor subscale of RLRS; raw score means; lower = better) · children and adolescents with a diagnosis of autism
1 finding from 1 review
Side effects or other adverse events · children and adolescents with a diagnosis of autism
1 finding from 1 review
Irritability · children and adolescents with a diagnosis of autism
1 finding from 1 review
Hyperactivity (Child Behaviour Checklist Attention problems Subscale; lower = better) · children and adolescents with a diagnosis of autism
1 finding from 1 review
General health and function (Severity of Illness subscale of Clinical Global Impression Scale; lower = better) · children and adolescents with a diagnosis of autism
1 finding from 1 review
Overall autism features (total score of RLRS; raw score means; lower = better) · children and adolescents with a diagnosis of autism
1 finding from 1 review
Social communication (Social Relationships subscale of RLRS; raw score means; lower = better) · children and adolescents with a diagnosis of autism
1 finding from 1 review
Cognitive function · vascular dementia and other vascular cognitive impairments
1 finding from 1 review
Clinical global impression: CIBIC‐Plus (Improvement) at 24 weeks 7‐point Likert scale · vascular dementia and other vascular cognitive impairments
Donepezil 5 mg leads to higher clinical global impression: CIBIC‐Plus (Improvement) at 24 weeks… compared with placebo (high certainty).
1 finding from 1 review
Functional outcomes · vascular dementia and other vascular cognitive impairments
1 finding from 1 review
Adverse events (all reported adverse events grouped) at 24 weeks · vascular dementia and other vascular cognitive impairments
Donepezil 5 mg showed no clear difference in adverse events (all reported adverse events grouped) at 24 weeks compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events (excluding death) at 24 weeks · vascular dementia and other vascular cognitive impairments
Donepezil 5 mg showed no clear difference in serious adverse events (excluding death) at 24 weeks compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events (excluding death) at 24 weeks · vascular dementia and other vascular cognitive impairments
Donepezil 10 mg showed no clear difference in serious adverse events (excluding death) at 24 weeks compared with placebo (moderate certainty).
1 finding from 1 review
Cognitive function · vascular dementia and other vascular cognitive impairments
1 finding from 1 review
Clinical global impression: CIBIC‐Plus (Improvement) at 24 weeks 7‐point Likert scale · vascular dementia and other vascular cognitive impairments
Donepezil 10 mg showed no clear difference in clinical global impression: CIBIC‐Plus (Improvement) at 24 weeks… compared with placebo (moderate certainty).
1 finding from 1 review
Functional outcomes · vascular dementia and other vascular cognitive impairments
1 finding from 1 review
Adverse events (all adverse events) at 24 weeks · vascular dementia and other vascular cognitive impairments
Donepezil 10 mg leads to higher adverse events (all adverse events) at 24 weeks compared with placebo (high certainty).
1 finding from 1 review